Recent industry estimates project the global anti-inflammatory therapeutics market to exceed USD 130 billion over the next decade, while the market for plant-derived pharmaceutical ingredients continues to expand as healthcare systems increasingly adopt environmentally sustainable and biologically compatible solutions. What was once largely associated with alternative
medicine is now evolving into a significant scientific and commercial movement within mainstream pharmaceuticals.
Against this backdrop, J & D Pharmaceuticals is positioning itself as a specialized innovator in plant-based salicylate therapeutics. Through its work on salicylsalicylic acid, the company is pursuing a strategic approach to redefine conventional anti-inflammatory treatment pathways by developing a molecule intended to provide analgesic and anti-inflammatory efficacy while minimizing the toxicities commonly linked to traditional NSAIDs. By integrating longevity-oriented research, rigorous clinical development, and sustainable pharmaceutical practices, J & D Pharmaceuticals is contributing to the broader transformation of inflammation management and healthy aging within the global healthcare industry.
See full article on India Pharma Outlook